Chemical formula: C₃₆H₄₁N₃O₆ Molecular mass: 611.727 g/mol PubChem compound: 65866
Lercanidipine is a calcium antagonist of the dihydropyridine group and inhibits the transmembrane influx of calcium into cardiac and smooth muscle. The mechanism of its antihypertensive action is due to a direct relaxant effect on vascular smooth muscle thus lowering total peripheral resistance.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| C08CA13 | Lercanidipine | C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ZANIDIP Film-coated tablet | Health Products Regulatory Authority (IE) | MPI, EU: SmPC |
Lercanidipine is an active ingredient of these brands:
Albania (AL)
Australia (AU)Austria (AT)Brazil (BR)
Croatia (HR)
Cyprus (CY)Ecuador (EC)
Estonia (EE)Finland (FI)France (FR)
Germany (DE)Hong Kong (HK)Ireland (IE)Israel (IL)
Italy (IT)
Lithuania (LT)
Malta (MT)
Poland (PL)
Romania (RO)South Africa (ZA)Spain (ES)Tunisia (TN)Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
